Cervical screening

New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, Other Health, Health, General Health, Women, Oncology, Other Science, Medical devices, Research, Consumer, Science, Cancer, Infectious causes of cancer, Human papillomavirus infection, Positive and negative predictive values, Cervical screening, HPV-positive oropharyngeal cancer

In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.

Key Points: 
  • In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.
  • The confidence that a positive test result truly indicated presence of disease (positive predictive value) was about the same for both LuViva (35%) and HPV (37%).
  • According to new U.S. guidelines, women with this high a likelihood of cervical disease or higher need to either have tissue removed for a definitive diagnosis or consider immediate treatment.
  • The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.

North America HPV Testing and Pap Test Market Potential, Industry Analysis and Forecast Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 6, 2021
Women, Other Health, Consumer, Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Carcinogens, Human papillomavirus infection, Pap test, Cervical cancer, HPV vaccine, Cervical screening

The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America HPV Testing and Pap Test Market By Type, By Application, By Product, By End Use, By Country, Growth Potential, Industry Analysis Report and Forecast, 2021 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, the growing number of cervical cancer cases may surge the demand for HPV testing and PAP tests, boosting the market growth.
  • Thus, the growing cases of cervical cancer across the North American region are expected to boost the demand for HPV testing and Pap test market over the forthcoming years.
  • The US market dominated the North America HPV Testing Market by Country 2020, thereby, achieving a market value of $844.5 million by 2027.

Global HPV Testing and Pap Test Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Oncology, Health, Consumer, Infectious diseases, Women, Other Health, Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Cervical screening, Pap test, Cervical cancer, Human papillomavirus infection, Cancer screening, Vagina, Screening, HPV vaccine

The "HPV Testing and Pap Test Market Size, Share & Trends Analysis Report by Test Type, by Application (Cervical Cancer Screening, Vaginal Cancer Screening), by Product, by Technology, by End Use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market Size, Share & Trends Analysis Report by Test Type, by Application (Cervical Cancer Screening, Vaginal Cancer Screening), by Product, by Technology, by End Use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global HPV testing and Pap test market size is expected to reach USD 7.3 billion by 2028.
  • In addition, approval of novel testing solutions and services to upsurge screening rates is further anticipated to support market growth.
  • Based on test type, the Pap test segment accounted for the largest revenue share in 2020, owing to its widespread use in cervical cancer screening programs.

Global Cervical Cancer Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021
Health, Oncology, Cancer, Infectious causes of cancer, Gynaecological cancer, Carcinogenesis, Cervical cancer, Epidemiology of cancer, Cervical cancer gene database, Cervical screening

The "Global Cervical Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cervical Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2021, provides Cervical Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Cervical Cancer patients, history of the disease at the population level (Cervical Cancer prevalence, Cervical Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Cervical Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Cervical Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Cervical Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Cervical Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005603/en/

Exact Sciences Applauds Final Task Force Recommendation That Lowers Starting Age for Colorectal Cancer Screening to 45

Retrieved on: 
Wednesday, May 19, 2021
Medicine, Clinical medicine, Cancer, Infectious causes of cancer, Cancer screening, United States Preventive Services Task Force, Medical terminology, Colorectal cancer, Screening, Prostate cancer screening, Cervical screening

b'MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.

Key Points: 
  • b'MADISON, Wis., May 18, 2021 /PRNewswire/ -- The United States Preventive Services Task Force (USPSTF) today released its final colorectal cancer screening recommendation that screening begin at age 45.
  • "These final guidelines will encourage more clinicians to offer colorectal cancer screening to their patients starting at age 45.
  • Under these final guidelines, colorectal cancer screening remains a Grade A recommendation for people ages 50-75 and screening for ages 45 to 49 is a Grade B recommendation.
  • Cancer.

BD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples

Retrieved on: 
Thursday, May 13, 2021
Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Medicine, Papillomavirus, Cancer screening, Cervical screening, Human papillomavirus infection, Cervical cancer, Screening

"\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.

Key Points: 
  • "\nAt-home collection will help address the urgent public health challenge of reaching women who do not attend routine cervical cancer screening.
  • "HPV self-sampling makes screening accessible to women who don\'t participate in screening or have limited access to screening.
  • The BD OnclarityHPV Assay has FDA approval for clinical use in cytology-based screening with ASC-US triage, in co-testing paradigm, and in primary HPV screening.
  • For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo .\n'

Medscape's Public Health Group Launches CDC Colorectal Cancer Screening Provider Education Course

Retrieved on: 
Tuesday, May 11, 2021
Medicine, Health sciences, Medical terminology, Prevention, Infectious causes of cancer, Health, Cancer prevention, Colorectal cancer, Cancer, Screening, Preventive healthcare, Cervical screening

Jean Shapiro from CDC\'s Division of Cancer Prevention and Control explains, "Primary care providers can help ensure that patients receive appropriate colorectal cancer screening that can save lives.

Key Points: 
  • Jean Shapiro from CDC\'s Division of Cancer Prevention and Control explains, "Primary care providers can help ensure that patients receive appropriate colorectal cancer screening that can save lives.
  • These courses provide guidance for primary care providers on ways to improve the quality of colorectal cancer screening that their patients receive.
  • Dotson WD,et al.Stool-Based Colorectal Cancer Screening in the COVID-19 Era.
  • Five Things to Know About Colorectal Cancer Screening.

Israeli FemTech Company MobileODT, Engaged in Large Scale Government Cervical Cancer Screening Project

Retrieved on: 
Thursday, March 25, 2021
Gynaecological cancer, Infectious causes of cancer, Medicine, Clinical medicine, Health, Cancer screening, Medical tests, Women's health, Cervical screening, Cervical cancer, Screening, Cervical

TEL AVIV, Israel, March 25, 2021 /PRNewswire/ -- MobileODT , an Israeli Digital Health FemTech company that is producing the latest innovation in cervical cancer screening, is proud to announce that their Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic.

Key Points: 
  • TEL AVIV, Israel, March 25, 2021 /PRNewswire/ -- MobileODT , an Israeli Digital Health FemTech company that is producing the latest innovation in cervical cancer screening, is proud to announce that their Visual Check AI technology is supporting a large-scale government cervical cancer screening project in the Dominican Republic.
  • This proof of concept project was initiated as part of the company's strategic direction in providing cervical cancer screening at scale, utilizing Artificial Intelligence (AI) and Machine Learning (ML) capabilities.
  • In the past three months, 9,000 women were screened for cervical cancer with the EVA Visual Check AI technology.
  • "We are the only company in the world with an AI capability in cervical cancer screening ," says Leon Boston, MobileODT's CEO.

Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           

Retrieved on: 
Monday, March 15, 2021
Cancer, Infectious causes of cancer, Gynaecological cancer, Cervical cancer, Adenocarcinoma, Cervical screening, HspE7

This landmark clinical achievement will bring hope to women with advanced cervical cancer who are often younger than patients with other cancers.

Key Points: 
  • This landmark clinical achievement will bring hope to women with advanced cervical cancer who are often younger than patients with other cancers.
  • This is the largest Phase 3 randomized clinical trial in advanced cervical cancer and included women (median age: 51 years) with either squamous cell carcinoma or adenocarcinoma.
  • The use of Libtayo in cervical cancer is investigational and has not been fully reviewed by any regulatory authority.
  • Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced stages.

Medical expert warns thousands could die from HPV programming interrupted by Covid-19

Retrieved on: 
Thursday, March 4, 2021
Cancer, Infectious causes of cancer, Gynaecological cancer, Papillomavirus, Margaret Stanley, Sexually transmitted diseases and infections, Cervical screening, Human papillomavirus infection, Cervical cancer

One woman dies from cervical cancer every 2 minutes but HPV is a virus that can be beaten, if services are rolled out and taken up.

Key Points: 
  • One woman dies from cervical cancer every 2 minutes but HPV is a virus that can be beaten, if services are rolled out and taken up.
  • In higher income countries, cervical screenings have reduced from 70% to 30-40% and 32% of women are unlikely to attend appointments due to Covid-19 fears.
  • IPVS calls for everyone to 'Ask About HPV' speak to local politicians, healthcare practitioners and seek information at www.askabouthpv.org .
  • Professor Margaret Stanley, President of IPVS, says "It's unfathomable that there is such inequality in the roll-out of crucial, inexpensive medical care.